FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
BRISBANE, Calif., Oct. 31, 2016 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present how innovative pricing approaches, such as the company’s Responsible Pricing Model, can fortify existing incentives to bring therapies to the U.S. for neglected diseases during the Priority Review Voucher (PRV) Summit in Arlington, Va., November 2-3, 2016.
Dr. Durrant will also participate in a separate panel to discuss PRVs as a model to support the research and development of important medicines.
“The current PRV system is enlightened policy driving both immediate help, and future advancements, for neglected disease patients,” said Dr. Durrant. “We look forward to engaging in the conversation around serving the public health through these effective FDA incentives and responsible drug pricing.”
Details of the presentation and panel follow:
Title: Tackling Neglected Diseases through Responsible Pricing
Date: Wednesday, November 2, 2016
Time: 3:00 – 3:45 p.m. EDT
Presenter: Dr. Cameron Durrant, KaloBios Pharmaceuticals
Title: Panel: Priority Review Vouchers: A New Paradigm for Funding Research
Date: Wednesday, November 2, 2016
Time: 4:15 – 5:15 p.m. EDT
Participants: Xi Chen, PhD, Adena Partners Management; Dr. Cameron Durrant, KaloBios Pharmaceuticals; Charles Keller, MD, Children’s Cancer Therapy Development Institute; Curt H. LaBelle, MD, Global Health Investment Fund
For more information on the conference, please visit http://exlevents.com/priorityreviewvoucher/.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Kim Sutton Golodetz O: 212-838-3777 [email protected] Bruce Voss O: 310-691-7100 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
